Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis.
Calcinosis of juvenile dermatomyositis (JDM) is a crucial problem because it is refractory to various therapies. An 11-year-old boy who had been treated for JDM with interstitial pneumonia developed calcinosis of both legs despite treatment with corticosteroid and cyclosporin A. Images of his knees showed massive calcinosis with restricted range of motion. Probenecid was used to reduce calcinosis, resulting in remarkable improvement of calcinosis accompanied by normalization of serum phosphorus level and disability after 17 months of administration. We suggest that probenecid is useful for the treatment of calcinosis of JDM.
Nakamura
Hideki
H
The First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Japan. nakamura_hideki911@yahoo.co.jp
Kawakami
Atsushi
A
Ida
Hiroaki
H
Ejima
Eri
E
Origuchi
Tomoki
T
Eguchi
Katsumi
K
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002114:Calcinosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use; D003882:Dermatomyositis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007719:Knee Joint / Q000000981:diagnostic imaging / Q000503:physiopathology; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D011339:Probenecid / Q000627:therapeutic use*; D011859:Radiography; D016059:Range of Motion, Articular / Q000187:drug effects; D016896:Treatment Outcome; D014528:Uricosuric Agents / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D014528:Uricosuric Agents; D016572:Cyclosporine; D011239:Prednisolone; D011339:Probenecid